Table of Contents:
- Chapter 1. Research Methodology and Scope
- Market Segmentation and Scope
- Regional Coverage
- North America, Europe, Asia Pacific, Latin America, Middle East & Africa
- Objectives
- Research Methodology
- Primary Research
- Secondary Research
- Chapter 2. Executive Summary
- Market Landscape
- Market Size and Forecast
- Competitive Landscape
- Chapter 3. Hemophilia Market: By Product Type Market Trends, Size, and Future Outlook
- By Product Type Market Size (US$), CAGR (%), and Forecast (2023-2031)
- By Product Type Definitions, Technology Landscape
- By Product Type Market Drivers
- Launch of novel extended half-life factors
- Strong pipeline of gene therapy candidates
- Increasing diagnosis of hemophilia A
- By Product Type Market Restraints
- High costs of treatment
- Underdiagnosis in developing countries
- Chapter 4. Hemophilia Market: By Treatment Type Market Trends, Size, and Future Outlook
- By Treatment Type Market Size (US$), CAGR (%), and Forecast (2023-2031)
- By Treatment Type Definitions, Technology Landscape
- By Treatment Type Market Drivers
- Shift towards prophylaxis therapy
- Approvals of extended half-life factors
- Better payer coverage for prophylaxis
- By Treatment Type Market Restraints
- Affordability of factors in emerging markets
- Adherence to prophylaxis regimen
- Chapter 5. Hemophilia Market: By Therapy Market Trends, Size, and Future Outlook
- By Therapy Market Size (US$), CAGR (%), and Forecast (2023-2031)
- By Therapy Definitions, Technology Landscape
- By Therapy Market Drivers
- High industry focus on developing gene therapy
- Promising clinical data for novel non-factor agents
- Lower inhibitor rates with non-factor therapies
- By Therapy Market Restraints
- High costs of novel non-factor therapies
- Potential for pre-existing immunity against gene therapy vectors
- Chapter 6. Hemophilia Market: By Age Group Market Trends, Size, and Future Outlook
- By Age Group Market Size (US$), CAGR (%), and Forecast (2023-2031)
- By Age Group Definitions, Technology Landscape
- By Age Group Market Drivers
- earlier diagnosis through newborn screening
- specific guidelines for pediatric prophylaxis therapy
- bespoke devices for home infusion in children
- By Age Group Market Restraints
- Transition of care from pediatric to adult services
- Lack of clinical data on novel therapies in children
- Chapter 7. Hemophilia Market: By Distribution Channel Market Trends, Size, and Future Outlook
- By Distribution Channel Market Size (US$), CAGR (%), and Forecast (2023-2031)
- By Distribution Channel Definitions, Technology Landscape
- By Distribution Channel Market Drivers
- Increasing supply of clotting factors to retail pharmacies
- Online pharmacies improving access and affordability in remote areas
- Use of mobile specialty clinics in rural areas
- By Distribution Channel Market Restraints
- Lack of cold chain infrastructure hindering distribution
- Counterfeiting risk with online pharmacies
- Chapter 8. Hemophilia Market: Regional Market Trends, Size, and Future Outlook
- North America Market Size (US$), CAGR (%), and Forecast (2023-2031)
- North America Definitions, Technology Landscape
- North America Market Drivers
- High diagnosis and treatment rates
- Favorable reimbursement policies
- Access to innovative therapies
- North America Market Restraints
- Pressure to reduce healthcare costs
- Europe Market Size (US$), CAGR (%), and Forecast (2023-2031)
- Europe Definitions, Technology Landscape
- Europe Market Drivers
- Established healthcare infrastructure
- Public awareness and education programs
- Strong network of comprehensive care centers
- Europe Market Restraints
- Budget constraints slowing adoption of novel therapies
- Asia Pacific Market Size (US$), CAGR (%), and Forecast (2023-2031)
- Asia Pacific Definitions, Technology Landscape
- Asia Pacific Market Drivers
- Large undiagnosed patient pool
- Growing healthcare expenditure
- Industry focus on expanding access
- Asia Pacific Market Restraints
- Limited public funding and reimbursement
- Lack of treatment infrastructure
- Latin America Market Size (US$), CAGR (%), and Forecast (2023-2031)
- Latin America Definitions, Technology Landscape
- Latin America Market Drivers
- Expanding diagnosis and screening programs
- Local manufacturing improving clotting factor availability
- Latin America Market Restraints
- High treatment costs due to lack of public funding
- Middle East & Africa Market Size (US$), CAGR (%), and Forecast (2023-2031)
- Middle East & Africa Definitions, Technology Landscape
- Middle East & Africa Market Drivers
- Increased hemophilia camps and outreach programs
- Charitable access programs by companies
- Middle East and Africa Market Restraints
- Low public health priority for rare diseases
- Minimal reimbursement policies
- Chapter 9. Hemophilia Market: Competitive Landscape
- Takeda
- Company Overview
- Financial Performance
- Product Portfolio
- Recent Developments
- CSL Behring
- Company Overview
- Financial Performance
- Product Portfolio
- Recent Developments
- Pfizer
- Company Overview
- Financial Performance
- Product Portfolio
- Recent Developments
- BioMarin
- Company Overview
- Financial Performance
- Product Portfolio
- Recent Developments
- Roche
- Company Overview
- Financial Performance
- Product Portfolio
- Recent Developments
- Novo Nordisk
- Company Overview
- Financial Performance
- Product Portfolio
- Recent Developments
- Sanofi
- Company Overview
- Financial Performance
- Product Portfolio
- Recent Developments
- Bayer
- Company Overview
- Financial Performance
- Product Portfolio
- Recent Developments
- Octapharma
- Company Overview
- Financial Performance
- Product Portfolio
- Recent Developments
- Grifols
- Company Overview
- Financial Performance
- Product Portfolio
- Recent Developments
- Swedish Orphan Biovitrum
- Company Overview
- Financial Performance
- Product Portfolio
- Recent Developments
- Biogen
- Company Overview
- Financial Performance
- Product Portfolio
- Recent Developments
- Freeline Therapeutics
- Company Overview
- Financial Performance
- Product Portfolio
- Recent Developments
- Sangamo Therapeutics
- Company Overview
- Financial Performance
- Product Portfolio
- Recent Developments
- Spark Therapeutics
- Company Overview
- Financial Performance
- Product Portfolio
- Recent Developments
- uniQure
- Company Overview
- Financial Performance
- Product Portfolio
- Recent Developments
- Catalyst Biosciences
- Company Overview
- Financial Performance
- Product Portfolio
- Recent Developments
- Dimension Therapeutics
- Company Overview
- Financial Performance
- Product Portfolio
- Recent Developments
- Eloxx Pharmaceuticals
- Company Overview
- Financial Performance
- Product Portfolio
- Recent Developments
- ObsEva
- Company Overview
- Financial Performance
- Product Portfolio
- Recent Developments
- Takeda
- Research Methodology
- Primary Research
- Secondary Research
- Assumptions
- Our Analysis
- Paid Database Sources
- Appendix
- About Us
Frequently Asked Questions
The current market size is USD 12.1 billion in 2023
Development of extended half-life factor concentrates, Emergence of prophylaxis as standard of care, Advances in gene therapy, Expanded access in emerging markets, Increased diagnosis rates
High cost of treatment, Underdiagnosis in developing countries, Formation of inhibitors, Limited reimbursement in some markets
Hemophilia A is the leading segment due to higher patient pool and ongoing research.
Takeda, CSL Behring, Pfizer, BioMarin, Roche, Sanofi, Novo Nordisk, Bayer, Grifols, and Octapharma.
CAGR of 4.5% Market size of $17.2 billion in 2031
Novel therapies like gene therapy and RNAi, Prophylaxis becoming standard of care, Extended half-life factors requiring less frequent dosing, Improved diagnostics and screening, Rising awareness and access in emerging markets